Ahmedabad, Jul 28 (UNI) Pharmaceutical and biotechnology major Wockhardt Limited today announced a Operating profit growth of 51.6 per cent at Rs 230.8 crore and 48.3 per cent increase in consolidated sales revenues to stand at Rs 935 crore for the second quarter ended June 30, 2008 over the corresponding quarter of 2007.
The overall US business grew by 128 per cent, while European business grew by 30 per cent in Q2 of 2008. Wockhardt USA Inc. and Morton Grove Pharmaceuticals having gained critical mass are showing phenomenal growth and are performing as per target plans.
Wockhardt Limited is a global pharmaceutical and biotechnology major with an innovative research and development programme.
UNI PVN RN SK RAI2302